Estimating the Health-Related Quality of Life Benefit of Prophylactic Treatment for COVID-19 in Immunocompromised People: A Multimethod Valuation Study.

IF 2.3 Q2 ECONOMICS Journal of Health Economics and Outcomes Research Pub Date : 2024-07-24 eCollection Date: 2024-01-01 DOI:10.36469/001c.120605
Katy Gallop, Rebekah Hall, Michael Watt, Daniel Squirrell, Neil Branscombe, Sofie Arnetop, Andrew Lloyd
{"title":"Estimating the Health-Related Quality of Life Benefit of Prophylactic Treatment for COVID-19 in Immunocompromised People: A Multimethod Valuation Study.","authors":"Katy Gallop, Rebekah Hall, Michael Watt, Daniel Squirrell, Neil Branscombe, Sofie Arnetop, Andrew Lloyd","doi":"10.36469/001c.120605","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Pre-exposure prophylaxis (PrEP) for COVID-19 provides additional protection, beyond vaccines alone, for individuals who are immunocompromised (IC). This may reduce the need for preventative behavioral modification, such as shielding-a behavioral restriction limiting an IC individual to minimize face-to-face interactions and/or crowded places. Therefore, PrEP may improve psychosocial well-being and health-related quality of life (HRQoL) for individuals with IC conditions. <b>Objective:</b> To estimate the potential HRQoL and utility benefit of PrEP for prevention of COVID-19 in individuals with IC conditions who may not have an adequate response of full vaccination (and therefore are at \"highest risk\" of severe COVID-19) that can be used in future economic evaluations of preventative therapies against COVID-19. <b>Methods:</b> Vignettes describing HRQoL associated with 2 pre-PrEP states (shielding and semi-shielding behavioral restrictions) and a post-PrEP state were developed from a literature review and tested through interviews with clinicians (n = 4) and individuals with IC conditions (n = 10). Vignettes were valued by a general population sample (N = 100) using a visual analog scale (VAS), time trade-off (TTO), and EQ-5D-5L. A sample of individuals with IC conditions (n = 48) valued their current HRQoL and a post-PrEP vignette using VAS and EQ-5D-5L. <b>Results:</b> Individuals with IC conditions reported a mean current EQ-5D-5L score of 0.574, and 0.656 for post-PrEP based on the vignette. PrEP would lead to behavior changes for 75% (30/40) of individuals with IC conditions and an emotional benefit for 93% (37/40) of individuals with IC conditions. Mean values from the general population valuation based on EQ-5D-5L ranged from 0.606 (\"shielding\") to 0.932 (\"post-PrEP\"). <b>Conclusion:</b> This study quantified the expected health state utility benefit of reduced psychosocial burden and behavioral restriction. PrEP would potentially result in a utility gain between 0.082 and 0.326, dependent on valuation approach and expected change in behavioral restrictions, leading to improvements in daily activities and emotional well-being.</p>","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"11 2","pages":"20-28"},"PeriodicalIF":2.3000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11276479/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Health Economics and Outcomes Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36469/001c.120605","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Pre-exposure prophylaxis (PrEP) for COVID-19 provides additional protection, beyond vaccines alone, for individuals who are immunocompromised (IC). This may reduce the need for preventative behavioral modification, such as shielding-a behavioral restriction limiting an IC individual to minimize face-to-face interactions and/or crowded places. Therefore, PrEP may improve psychosocial well-being and health-related quality of life (HRQoL) for individuals with IC conditions. Objective: To estimate the potential HRQoL and utility benefit of PrEP for prevention of COVID-19 in individuals with IC conditions who may not have an adequate response of full vaccination (and therefore are at "highest risk" of severe COVID-19) that can be used in future economic evaluations of preventative therapies against COVID-19. Methods: Vignettes describing HRQoL associated with 2 pre-PrEP states (shielding and semi-shielding behavioral restrictions) and a post-PrEP state were developed from a literature review and tested through interviews with clinicians (n = 4) and individuals with IC conditions (n = 10). Vignettes were valued by a general population sample (N = 100) using a visual analog scale (VAS), time trade-off (TTO), and EQ-5D-5L. A sample of individuals with IC conditions (n = 48) valued their current HRQoL and a post-PrEP vignette using VAS and EQ-5D-5L. Results: Individuals with IC conditions reported a mean current EQ-5D-5L score of 0.574, and 0.656 for post-PrEP based on the vignette. PrEP would lead to behavior changes for 75% (30/40) of individuals with IC conditions and an emotional benefit for 93% (37/40) of individuals with IC conditions. Mean values from the general population valuation based on EQ-5D-5L ranged from 0.606 ("shielding") to 0.932 ("post-PrEP"). Conclusion: This study quantified the expected health state utility benefit of reduced psychosocial burden and behavioral restriction. PrEP would potentially result in a utility gain between 0.082 and 0.326, dependent on valuation approach and expected change in behavioral restrictions, leading to improvements in daily activities and emotional well-being.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
估算免疫力低下人群预防性治疗 COVID-19 带来的与健康相关的生活质量效益:多方法估值研究》。
背景:针对 COVID-19 的暴露前预防 (PrEP) 可为免疫力低下 (IC) 的个体提供额外的保护,而不仅仅是疫苗。这可能会减少对预防性行为矫正的需求,如屏蔽--一种限制 IC 感染者尽量减少面对面交流和/或到拥挤场所的行为限制。因此,PrEP 可以改善 IC 患者的社会心理健康和与健康相关的生活质量(HRQoL)。目的估算PrEP在预防COVID-19方面可能为IC患者带来的潜在HRQoL和效用益处,这些患者可能对完全接种疫苗没有足够的反应(因此处于严重COVID-19的 "最高风险"),这些益处可用于未来对COVID-19预防疗法的经济评估。方法:根据文献综述编写了描述与 2 种接种前状态(屏蔽和半屏蔽行为限制)和 1 种接种后状态相关的 HRQoL 的小故事,并通过与临床医生(n = 4)和 IC 患者(n = 10)的访谈进行了测试。普通人群样本(100 人)使用视觉模拟量表(VAS)、时间权衡(TTO)和 EQ-5D-5L 对小故事进行了评估。患有集成电路疾病的样本(48 人)使用 VAS 和 EQ-5D-5L 对其当前的 HRQoL 和 PrEP 后的小故事进行评估。结果:患有集成电路疾病的个体报告称,其目前的 EQ-5D-5L 平均得分为 0.574,而根据小故事,PrEP 后的 EQ-5D-5L 平均得分为 0.656。75%(30/40)的 IC 患者会因 PrEP 而改变行为,93%(37/40)的 IC 患者会因 PrEP 而获得情感上的益处。基于 EQ-5D-5L 的普通人群评估平均值从 0.606("屏蔽")到 0.932("PrEP 后")不等。结论本研究量化了减轻社会心理负担和行为限制的预期健康状态效用效益。PrEP 有可能带来 0.082 到 0.326 之间的效用收益,这取决于估价方法和行为限制的预期变化,从而改善日常活动和情绪福祉。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.00
自引率
0.00%
发文量
55
审稿时长
10 weeks
期刊最新文献
We Are on the Verge of Breakthrough Cures for Type 1 Diabetes, but Who Are the 2 Million Americans Who Have It? Retrospective Analysis of RSV Infection in Pediatric Patients: Epidemiology, Comorbidities, Treatment, and Costs in Dubai (2014-2023). Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes. Assessing the Fiscal Burden of Overweight and Obesity in Japan through Application of a Public Economic Framework. Healthcare Resource Utilization Among Patients With Agitation in Alzheimer Dementia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1